CD56+ Cell Depletion From Human PBMCs Applied To Validate A HIV-Specific ADCC Mechanism

Even though our knowledge of the virus and disease progression of HIV has increased a lot over the last three decades, there is currently no effective vaccine or cure. One limitation to study the course of infection and therapeutic candidates has been the lack of suitable small animal models, as HIV only infects human cells.

A laboratory working on HIV-1 immunology and studying various ways to enhance effector cell activity against HIV-infected cells used the Goldstein Lab's hu-spl-PBMC-NSG model to test the efficacy of broadly neutralizing antibodies (bNAb) against HIV, and specifically to study bNAb antibody-dependent cellular cytotoxicity (ADCC) activity. Explore results from utilizing an in vivo model to study the ADCC activity of antibodies to clear HIV-infected cells.